Mizuho Downgrades Acadia Pharmaceuticals (ACAD) to Neutral, 'Disappointing ADVANCE-2 Data'
Tweet Send to a Friend
(Updated - March 12, 2024 3:40 AM EDT)Mizuho analyst Uy Ear downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Buy to Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
